Foundations of Care

Stopping Wegovy: what happens to your body and how to keep the weight off

Sword Editorial Team

Search for your health plan or employer

Footnotes

  1. 1

    Prado CM, Wells JC, Smith SR, Stephan BCM, Siervo M. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology. 2024;12(11):785-787.

  2. 2

    Karakasis P, et al. [Use exact approved source from claims bank for GLP-1 lean mass range before publish.]

  3. 3

    Wilding JPH, Batterham RL, Calanna S, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/

  4. 4

    Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021;384(18):1719-1730.

  5. 5

    World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2025.

  6. 6

    Kim DD, et al. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. JAMA Network Open. 2024;7(5):e2415815.

  7. 7

    Baumgartner RN, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obesity Research. 2004;12(12):1995-2004.

  8. 8

    Sousa AS, et al. Impact of sarcopenia on fall risk: a clinical perspective. Clinical Nutrition ESPEN. 2022;50:63-73.

  9. 9

    Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Network Open. 2024;7(6):e2416775.

  10. 10

    Sandsdal RM, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome. Cardiovascular Diabetology. 2023;22:41.

  11. 11

    Sword Health. Move Book of Business data. 2023.

Portugal 2020Norte 2020European UnionPlano de Recuperação e ResiliênciaRepública PortuguesaNext Generation EU